Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer

This article was originally published here

Oncol Lett. Jan 2022; 23 (1): 6. doi: 10.3892 / ol.2021.13124. Online publication of November 5, 2021.


Three-dimensional (3D) organoid culture systems emerge as potential reliable tools for studying the basic developmental processes of human diseases, in particular cancer. The present study used established and modified culture conditions to report the successful generation and characterization of patient-derived organoids from fresh primary tissue samples from patients with naive prostate cancer (PCa). processing. Fresh tissue samples were collected, enzymatically digested and the resulting cell suspensions were plated in a 3D environment using Matrigel as an extracellular matrix. The 12-factor medium previously established for the organoid culture was modified to create a minimal 5-factor medium. Organoids and corresponding tissue samples were characterized using transcriptomic analysis, immunofluorescence analysis, and immunohistochemistry. In addition, organoids derived from the patient were used to assess the response to the drug. PCa organoids derived from treatment naïve patients were obtained from fresh radical prostatectomy specimens. These PCa organoids mimicked the heterogeneity of the corresponding parental tumor tissue. Histopathological analysis demonstrated similar tissue architecture and cell morphology, as well as consistent immunohistochemical marker expression. In addition, the results confirmed the potential of organoids as in vitro model to assess potential personalized therapeutic responses, as there was a differential drug response between different patient samples. In conclusion, the present study examined organoids derived from a cohort of treatment-naïve patients. The derived organoids mimicked the histological features and prostate lineage profiles of their corresponding parental tissue and could present a potential model for predicting patient-specific treatment response in a preclinical setting.

PMID:348202005 | PMC:PMC8607232 | DO I:10.3892 / ol.2021.13124

Comments are closed.